SOBR Safe, Inc. - Common Stock (SOBR)

EQNX::TICKER_START (NASDAQINBS),NASDAQ:CDIONASDAQCDIO)(NASDAQ:BIAFNASDAQBIAF,(NASDAQ:TRIBNASDAQ),(NASDAQ:SOBRSOBR) EQNX::TICKER_END

SOBR Safe (NASDAQSOBR) (“SOBRsafe”), a provider of next-generation transdermal alcohol detection technology, recently announced the launch of its fully integrated enterprise software solution that is expected to transform how health providers monitor and manage alcohol compliance. “To complement its software solution for point-of-care screening SOBRcheck(TM) and continuous monitoring SOBRsure(TM), this enterprise software is designed to enhance responsiveness to treatment, reduce recidivism and drive positive patient outcomes,” reads an article discussing the launch.

SOBR Safe (NASDAQSOBR) (“SOBRsafe”) is a provider of next-generation transdermal alcohol screening and monitoring solutions. The company recently launched a national campaign that seeks to introduce its technology offerings – the SOBRcheck(TM) stationary alcohol screening device, the SOBRsure(TM) discreet alcohol monitoring wristband, and the SOBRsafe(TM) software platform powering reporting – to behavioral health providers and, as a result, drive sales growth into 2025. “The company aims to present its technology to over 45,000 decision-makers in the behavioral health space, having partnered with recognized leaders in public relations and digital and social media marketing,” reads an article discussing the campaign.

Critical Infrastructure, Commercial Fleets and Family Law Highlight New Global Applications

PALM BEACH, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Due to the expanding consumption of illicit drugs & alcohol across the globe the Drug Screening market is poised to grow substantially in the coming years. Drug abuse and alcohol consumption are growing worldwide. According to the World Drug Report 2023, in 2021, 1 in every 17 people aged 15–64 in the world had used a drug in the past 12 months. The number of users grew from 240 million in 2011 to 296 million in 2021 or 5.8% of the global population aged 15-64. This is a 23% increase, partly due to population growth. Other drugs like Cannabis the second most used drug, with an estimated 219 million users i.e. 4.3% of the global adult population in 2021. In 2021, according to the US Department of Transportation, National Highway Traffic Safety Administration (NHTSA), 13,384 people died in alcohol-impaired driving crashes, i.e. a 14% rise from last year. A report from MarketsAndMarkets projected that: “The global drug screening market, valued at US$7.7 billion in 2023, is forecasted to grow at a robust CAGR of 16.6%, reaching US$9.1 billion in 2024 and an impressive US$19.5 billion by 2029.North America dominates the drug screening market. This market is projected to reach USD 9.3 billion by 2029, at a CAGR of 16.4% during the forecast period. The expanding consumption of illicit drugs & alcohol will advance raise the development of drug screening products & services on the road, thereby driving the overall market growth.”   Active companies in news today include:   Intelligent Bio Solutions Inc. (NASDAQINBS), Cardio Diagnostics Holdings, Inc. NASDAQ: CDIONASDAQCDIO)(NASDAQ: BIAFNASDAQBIAF, Trinity Biotech plc (NASDAQ: TRIBNASDAQ), SOBR Safe, Inc. (NASDAQ: SOBRSOBR).

SOBR Safe (NASDAQSOBR) (“SOBRsafe”), a provider of next-generation transdermal alcohol detection solutions, earlier this year began the sale of its SOBRsure(TM) wearable continuous alcohol monitoring device in Australia and New Zealand following a 90-day proof-of-concept. “This overseas milestone was made possible through an international channel partnership with Drug Testing Business Success, the leading drug and alcohol testing service provider in the region,” reads a recent article.

SOBRsafe (NASDAQSOBR), a Colorado-based provider of next-generation transdermal alcohol detection technology, has just announced the launch of its fully integrated enterprise software solution that is expected to transform how health providers monitor and manage alcohol compliance. Designed to complement its software solution for point-of-care screening (SOBRcheck(TM)) and continuous monitoring (SOBRsure(TM)), this enterprise software is designed to enhance responsiveness to treatment, reduce recidivism and drive positive patient outcomes ( https://ibn.fm/GGnkx ).

SOBRsafe (NASDAQSOBR) has released SOBRsure, a new wristband device that uses transdermal technology to detect alcohol levels through the skin, providing real-time monitoring to support sobriety and recovery. With a sleek, user-friendly design and GPS tracking, the device offers continuous alcohol detection, instant alerts, and the option to access historical reports through a premium subscription. CEO David Gandini emphasizes SOBRsure as both a technological breakthrough and a support system for individuals with alcohol use disorder, aiming to promote accountability and peace of mind for families, employers, and users. Available now, the wristband retails for $249, with subscriptions starting at $39.99 per month.

SOBRsafe (NASDAQSOBR), a provider of next-generation transdermal alcohol screening and monitoring solutions, recently raised $8.2 million in gross proceeds from a private placement with certain institutional investors. The company expects to use the net proceeds from the offering for working capital and general corporate purposes ( https://ibn.fm/xM074 ).

SOBR Safe (NASDAQSOBR) (“SOBRsafe”) develops and sells a passive, preventative alcohol screening device called the SOBRcheck(TM) and a continuous alcohol monitoring wristband called SOBRsure(TM). “SOBRcheck is fitted with two sensors, one of which scans biometrics data from a user’s fingerprint, with the other detecting any alcohol excreted from the pores in the tip of the finger. The device is powered by the SOBRsafe software platform, which relays results in real time, improving employee throughput at point-of-care facilities. The SOBRsure(TM) device is equally configured to provide app-based reporting via the SOBRsafe platform, support GPS tracking and send removal alerts,” a recent article reads.

SOBRsafe (NASDAQSOBR) announced its compliance with Nasdaq’s listing standards, meeting minimum bid price, public float, and stockholders’ equity requirements per the August 2024 Nasdaq Hearings Panel decision. As a result, SOBRsafe’s common stock will remain listed on the Nasdaq Capital Market. The company will undergo a one-year monitoring period starting Oct. 30, 2024, during which any recurrence of non-compliance with the stockholders’ equity rule will result in an immediate Delist Determination Letter, requiring a new hearing request without a compliance grace period.

DENVER, CO / ACCESSWIRE / October 31, 2024 / SOBR Safe, Inc. (NASDAQSOBR) ("SOBRsafe"), provider of next-generation transdermal alcohol detection solutions, today announced that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), the public float requirement under Nasdaq Listing Rule 5550(a)(4) and the stockholders' equity requirement (the "Equity Rule") under Nasdaq Listing Rule 5550(b)(1), as required by the Nasdaq Hearings Panel decision dated August 2024. Accordingly, the Company's common stock will continue to be listed and trade on The Nasdaq Capital Market under the symbol "SOBR".

SOBRsafe (NASDAQSOBR) has introduced an enterprise software platform that integrates its transdermal alcohol detection technologies, SOBRcheck and SOBRsure, into a streamlined dashboard for health providers. The system allows real-time monitoring of alcohol compliance across multiple users and locations, addressing inefficiencies in current testing methods. By offering instant, non-invasive detection of alcohol through the skin, the software aims to enhance treatment outcomes and improve organizational efficiency in behavioral health centers. The platform’s historical data tracking also aids compliance verification with third parties.

DENVER, CO / ACCESSWIRE / October 22, 2024 / SOBRsafe, Inc. (NASDAQSOBR) ("SOBRsafe"), the leader in next-generation transdermal alcohol detection technology, is proud to announce the launch of its fully-integrated enterprise software solution for point-of-care screening (SOBRcheck™) and continuous monitoring (SOBRsure™). This new innovative platform is expected to transform how health providers monitor and manage alcohol compliance, delivering unprecedented real-time visibility across multiple users and locations in one dynamic dashboard.

SOBR Safe (NASDAQSOBR) (“SOBRsafe”), the developer of advanced transdermal alcohol detection and monitoring technology, launched a national campaign targeting behavioral health providers. “SOBRsafe is undertaking the campaign in partnership with prominent national agencies drawn from the public relations and digital and social media marketing spaces. The campaign seeks to introduce the SOBRsafe(TM) technology to a large and growing market, and is designed to capture over 4 million projected views over the next year and present the technology to more than 45,000 behavioral health decision makers… The SOBRsafe(TM) technology is a scalable, patent-pending software platform, which integrates with the company’s non-invasive devices, the SOBRcheck(TM) and SOBRsure(TM), to produce statistical, measurable user and business data,” a recent article reads.

Early this year, SOBRsafe (NASDAQSOBR), a provider of next-generation transdermal alcohol detection solutions, announced that the sale of its SOBRsure(TM) wearable continuous alcohol monitoring device had begun in Australia and New Zealand following a 90-day proof-of-concept. This overseas milestone was made possible through an international channel partnership with Drug Testing Business Success, the leading drug and alcohol testing service provider in the region ( https://ibn.fm/3X0AI ). .

In 2015 and 2016, the National Institute on Alcohol Abuse and Alcoholism (“NIAAA”), a part of the National Institutes of Health (“NIH”), challenged innovators and entrepreneurs to create a “wearable or otherwise discreet device capable of measuring blood alcohol level in real-time.” The challenge aimed to help solve the disadvantages of the then-preferred technologies for alcohol monitoring.

SOBR Safe (NASDAQSOBR) (“SOBRsafe”), a provider of next-generation transdermal alcohol detection solutions, today announced the closure of a private placement with certain institutional investors. The offering, which consisted of 2,024,691 units issued by the company, raised aggregate gross cash proceeds of $8.2 million before deductions. SOBRsafe plans to use the net proceeds from the private placement for general corporate processes and working capital.

NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Aegis Capital Corp. acted as Exclusive Placement Agent on an $8.2 Million Private Placement for SOBR Safe, Inc. (NASDAQSOBR).

DENVER, CO / ACCESSWIRE / October 9, 2024 / SOBR Safe, Inc. (NASDAQSOBR) ("SOBRsafe"), provider of next-generation transdermal alcohol detection solutions, today announced the closing of a private placement with certain institutional investors. The aggregate gross cash proceeds were $8.2 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the private placement for general corporate purposes and working capital.

SOBRsafe (NASDAQSOBR ), a provider of next-generation, transdermal alcohol-detection solutions, has released certain information regarding a private placement. The placement, which is with certain institutional investors, is projected to result in an estimated $8.2 million for the company, before the deduction of standard fees and costs. SOBRsafe anticipates using the funds for working capital and general corporate purposes. The company plans on issuing 2,024,691 units in connection with the placement, with each unit sold at $4.05. The announcement noted that each unit will comprise one share of common stock (or one prefunded warrant in lieu thereof), two Series A warrants and one Series B warrant. The placement is expected to close today and is subject to customary closing conditions. Aegis Capital Corp. is acting as placement agent for the private placement.

DENVER, CO / ACCESSWIRE / October 7, 2024 / SOBR Safe, Inc. (NASDAQSOBR) ("SOBRsafe"), provider of next-generation transdermal alcohol detection solutions, today announced the pricing of a private placement with certain institutional investors. The aggregate gross cash proceeds are expected to be $8.2 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the private placement for general corporate purposes and working capital.

SOBRsafe (NASDAQSOBR), a provider of next-generation, transdermal alcohol-detection solutions, is reporting on potential international expansion into three markets: India, Italy and Australia/New Zealand. According to the report, the company was approached by interested parties in all three regions regarding utilization of SOBRsafe technologies. In India, an infrastructure developer has designated SOBRsafe for a paid proof-of-concept (“POC”) installation in a public, safety-sensitive facility. In Italy, a global employer is leveraging SOBRsafe for a paid POC application of its proprietary wristband for the company’s fleet drivers. In Australia/New Zealand, the company has partnered with a leading drug- and alcohol-testing service provider in the region to begin sales efforts. In addition, approval from courts in both countries have been obtained to use SOBRsafe technology in family law cases.

SOBRsafe (NASDAQSOBR), a company leveraging its advanced next-generation transdermal alcohol detection technology to empower recovery, recently shared a video update from CEO and Chairman Dave Gandini. In the update, Gandini discussed the company’s approved compliance strategies to ensure continued listing on the Nasdaq Capital Markets ( https://ibn.fm/Uy9XX ).

DENVER, CO / ACCESSWIRE / September 30, 2024 / SOBR Safe, Inc. (NASDAQSOBR) ("SOBRsafe"), provider of next-generation transdermal alcohol detection solutions, today announced that it will proceed with a 1-for-110 reverse stock split ("Reverse Stock Split") of its outstanding shares of common stock (the "Common Stock") following approval by its board of directors. This ratio is within the range approved by stockholders at the annual meeting of SOBRsafe's shareholders held on June 3, 2024.